rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ZLAB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Zai Lab: The China Engine Pays The Bills, Zoci Could Pay The Upside (Initiating Buy)
      13h agoSeeking AlphaZLAB
      Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
      Nov 14Yahoo FinanceZLAB
      Zai Lab Announces Participation in Investor Conferences in November 2026

      SHANGHAI & CAMBRIDGE, Mass., November 13, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2026:

      Nov 13Yahoo FinanceZLAB
      Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
      Nov 13BenzingaZLAB
      Zai Lab reports phase 1 trial results for atopic dermatitis drug
      Nov 13Investing.comZLAB
      Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
      Nov 13Yahoo FinanceZLAB
      Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
      Nov 10Yahoo FinanceZLAB
      Zai Lab stock hits 52-week high at 27.62 USD
      Nov 9Investing.comZLAB
      Why Zai Lab Stock Is Up 12.7% And What's Next
      Nov 7Yahoo FinanceZLAB
      Zai Lab Ltd (ZLAB) Q3 2026 Earnings Call Highlights: Stabilizing China Business, Breakthrough ...

      Zai Lab Ltd (ZLAB) posted $108.2 million in Q3 2026 revenue with a profitable China commercial business, $659.7 million in cash, and plans for a potential U.S. BLA submission for ZOSI in 2027.

      Nov 7Yahoo FinanceZLAB
      Zai Lab Q3 Earnings Call Highlights
      Nov 7Yahoo FinanceZLAB
      Zai Lab Q3 2026 Earnings Call Transcript
      Nov 5BenzingaZLAB
      Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas

      SHANGHAI & CAMBRIDGE, Mass., November 05, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that updated data from a Phase 1b/2 trial of zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), will be shared tomorrow at the North American Neuroendocrine Tumor Society (NANETS) 2026 Multidisciplinary NET Medical Symposium in Las Vegas. The data indicate that zoci demonstrated clinically meaning

      Nov 5Yahoo FinanceZLAB
      Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
      Nov 5Yahoo FinanceZLAB
      Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
      Nov 5Yahoo FinanceZLAB
      Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer - Slideshow (NASDAQ:ZLAB) 2026-10-27
      Oct 27Seeking AlphaZLAB
      Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study
      Oct 23Yahoo FinanceZLAB
      Why is Zai Lab stock surging today?
      Oct 23Investing.comZLAB
      Zai Lab reports phase 1b trial data for lung cancer treatment
      Oct 23Investing.comZLAB
      Zai Lab to Privately Place $250 Million in ADRs to Fund Drug Research
      Oct 23Yahoo FinanceZLAB
      Zai Lab raises $250 million in private placement financing
      Oct 23Investing.comZLAB
      Zai Lab Announces $250 Million Private Placement
      Oct 23Yahoo FinanceZLAB
      Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
      Oct 21Yahoo FinanceZLAB
      Cantor Fitzgerald reiterates Zai Lab stock rating on ADC potential
      Oct 6Investing.comZLAB
      Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript - Zai Lab (NASDAQ:ZLAB)

      Zai Lab (NASDAQ:ZLAB) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings

      Oct 5BenzingaZLAB
      Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?

      ESMO data disclosure puts Zai Lab’s early lung cancer program in focus Zai Lab (ZLAB) has put fresh attention on its pipeline after confirming that global Phase 1b/1c data for zocilurtatug pelitecan in extensive-stage small cell lung cancer will appear at the ESMO Congress 2026. The ESMO update lands after a mixed period for Zai Lab, with the share price down 7.24% over the past 30 days, yet up 27.52% on a 90 day basis and 40.39% year to date, while the 1 year total shareholder return is...

      Oct 4Yahoo FinanceZLAB
      The Insider Report: The Leaders Have Taken Off - DexCom (NASDAQ:DXCM), Zai Lab (NASDAQ:ZLAB)

      Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the

      Sep 28BenzingaDXCMZLAB
      Zai Lab Ltd (1ZLB) Receives a Buy from UBS

      Detailed price information for Zai Lab Ltd ADR (ZLAB-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailZLAB
      Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks

      Zai Lab stock presents a challenging valuation picture for investors, with a share price that has risen in the shorter term but sits against a five year record of heavy value loss and only a mixed read from broader valuation checks. The share price has fallen 80.9% over the past five years, which points to a significant destruction of shareholder value over a full market cycle. Future revenue growth from its biopharmaceutical portfolio can support the current valuation, while ongoing...

      Sep 6Yahoo FinanceZLAB
      Guotai Haitong Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)

      Tipranks Press Release.

      Aug 27The Globe and MailZLAB

      This is the newest page. Registered accounts read further back.